Peripheral Arterial Disease (PAD) Clinical Trial
Official title:
Randomized Trial of IN.PACT Admiral(TM) Drug Coated Balloon vs Standard PTA for the Treatment of SFA and Proximal Popliteal Arterial Disease
The objective of this Study is to evaluate the safety and efficacy of the IN.PACT Admiral® drug coated PTA balloon, utilized for the dilatation of the narrowed sections of the artery, as compared to other standard (non drug coated) PTA balloons. The IN.PACT Admiral, besides the mechanical dilatation effect typical of all PTA balloons, releases a drug (paclitaxel) from the balloon surface into the vessel walls. This drug absorption is intended to limit the chances and the entity of artery re-narrowing over time.
The efficacy of the IN.PACT Admiral balloon will be evaluated by assessing the primary
patency rate of the treated arteries in the thighs of all patients included in the Study.
Primary patency is a measure of the durability up to 1 year of the free lumen in the artery
as restored during the procedure and is based on:
- the need for re-dilatation of the previously treated vessel segment
- an ultrasound examination The safety of the IN.PACT Admiral will be assessed by
evaluating the incidence of deaths, amputations and re-dilatation of the pre-treated
arteries in all patients included in the Study.
The IN.PACT SFA Trial enrolled in 2 phases: IN.PACT SFA I and IN.PACT SFA II. The
150-patient IN.PACT SFA I phase is intended to support the second phase IN.PACT SFA II IDE
trial with congruent design and protocol. Aggregate data from the two phases is intended to
provide statistical power for the 12-month primary safety and effectiveness endpoints.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT00707876 -
Magnetic Resonance Angiography for Peripheral Arterial Disease (PAD)
|
Phase 2 | |
| Completed |
NCT00760565 -
A Multiple Ascending Dose Study of RO4905417 in Healthy Volunteers and Patients With Peripheral Arterial Disease (PAD).
|
Phase 1 | |
| Recruiting |
NCT04631848 -
ULTRASCORE™ Focused Force PTA Balloon Angioplasty for CLI Patients With Below the Knee Vessel Disease
|
||
| Completed |
NCT00196066 -
Evaluation of the Zilver Vascular Stent in the Iliac Arteries (ZIPS)
|
Phase 2 | |
| Recruiting |
NCT05834673 -
VICTORION-ASCERTAIN: Implementation Study (v-ASCERTAIN)
|
Phase 4 | |
| Recruiting |
NCT05498740 -
Post-marketing Study in Femoral Popliteal Artery of Drug Coated Balloon Used for Treatment of Lower Limb Ischemia
|
N/A | |
| Completed |
NCT02780349 -
Evaluation of WIRION™ EPS in Lower Extremities Arteries
|
N/A | |
| Completed |
NCT02254837 -
Zilver PTX Post-Market Study in Japan
|
N/A | |
| Completed |
NCT02254356 -
Zilver Flex Post-Market Study in Japan
|
N/A | |
| Completed |
NCT00689377 -
Prevalence of Peripheral Arterial Disease in Subject With a Moderate Risk of Cardiovascular (CV) Disease (CVD) in Primary Prevention
|
N/A | |
| Active, not recruiting |
NCT05149664 -
A Non-significant Risk Clinical Study: Changes in Perfusion After Therapeutic Ultrasound in Patients With PAD
|
N/A | |
| Recruiting |
NCT04749732 -
Home-based Exercise Therapy for Patients With PAD
|
N/A | |
| Completed |
NCT02936622 -
Paclitaxel-coated Peripheral Stents Used in the Treatment of Femoropopliteal Stenoses
|
N/A | |
| Completed |
NCT00862420 -
Safety Evaluation of Clopidogrel Sulfate in Patients With Peripheral Arterial Disease
|
Phase 3 | |
| Completed |
NCT00827619 -
Zilver® Flex™ Vascular Stent Study
|
N/A | |
| Completed |
NCT04753372 -
Rivaroxaban Plus Aspirin in Patients With Chronic Coronary Syndrome and High Ischemic Risk
|
||
| Recruiting |
NCT05246410 -
A Clinical Trial to Evaluate the Efficacy and Safety of a Spot Stent System Used in Femoropopliteal Arteries.
|
N/A | |
| Terminated |
NCT03111238 -
The Efficacy and Safety of REX-001 to Treat Ischemic Rest Pain in Subjects With CLI Rutherford Category 4 and DM
|
Phase 3 | |
| Terminated |
NCT03174522 -
The Efficacy and Safety of REX-001 to Treat Ischemic Ulcers in Subjects With CLI Rutherford Category 5 and DM
|
Phase 3 |